NOT FDA-APPROVED

Selank

A Russian-developed anti-anxiety nasal spray. Approved as a prescription medication in Russia. Not approved by the FDA. Calmer focus without the sedation or dependence concerns of benzodiazepines.

The 30-second read

Selank is a synthetic seven-amino-acid peptide derived from a natural immune-modulating fragment called tuftsin. It was developed in Russia as an anti-anxiety medication and has been a registered prescription drug there since 2009. Russian clinical research suggests it reduces anxiety with cognitive benefits, and without the sedation, dependency, or memory issues that come with benzodiazepines. It's used as a nasal spray. Not FDA-approved, and almost all the published clinical research is from Russian institutes. Mechanism plausibly involves GABA modulation and serotonergic effects, but the molecule has not been put through Western-style RCTs.

Why this peptide is on people's radar

The pitch for Selank is straightforward: an anxiety medication that doesn't sedate you, doesn't impair memory, and doesn't carry dependency risk. That's a meaningful gap in the conventional anti-anxiety toolkit. Benzodiazepines work but bring sedation, cognitive blunting, and dependence. SSRIs take weeks to kick in and have their own side-effect profile. Selank, in the Russian clinical literature, is positioned as something that takes the edge off without the trade-offs.

Selank emerged from the same Russian neuropeptide research tradition as Semax, both were developed by the Institute of Molecular Genetics in Moscow and the Research Institute of Pharmacology of the Russian Academy of Medical Sciences. Both became registered prescription drugs in Russia. Both are used as nasal sprays. Outside Russia, neither has been put through the modern Western-style trial pipeline that would lead to FDA approval.

In nootropic and biohacker communities, Selank has been a quiet staple for years, usually framed as a daily-use option for people whose work or personal life involves chronic mild-to-moderate anxiety. The mechanism of action involves GABA modulation, serotonergic effects, and immune signaling, which is unusually broad for an anxiolytic. Whether the broad mechanism translates into broad real-world effect is the question.

What people are usually trying to do with it

People exploring Selank are usually focused on:

  • Reducing daily anxiety without the sedation of benzodiazepines
  • Staying sharp under stress, an alternative to "calm but foggy"
  • Avoiding the dependency risks that come with GABA-A drugs
  • Adding an anti-anxiety option to a nootropic stack
  • Supporting sleep that's disrupted by anxiety
  • Using a convenient nasal spray rather than a daily pill

What the science actually shows

The Russian clinical literature is more substantial than skeptics realize, and far less rigorously peer-reviewed (in the Western sense) than enthusiasts realize. Plain-English summary:

Anxiolytic effect (Russian clinical literature)

Multiple Russian clinical studies report reductions in anxiety scores in patients with generalized anxiety disorder and adjustment disorders, comparable to medazepam (a benzodiazepine) without sedation or memory impairment.12

Cognitive preservation

A claimed advantage over benzodiazepines: Russian studies report that Selank does not impair attention, memory, or psychomotor performance. Some studies report mild cognitive enhancement.3

Mechanism. GABA, serotonin, BDNF

Mechanistic studies (animal and cell culture) suggest Selank modulates GABA-A receptor expression, affects serotonergic neurotransmission, and may increase BDNF (a growth factor associated with neuroplasticity).4

Immune modulation

Selank derives from tuftsin, a naturally occurring immunomodulating peptide. Some studies report immune-stimulating effects relevant to people whose anxiety includes a stress-immune component.5

What hasn't been demonstrated

Replication of the Russian clinical findings by Western research groups using modern RCT methodology. Long-term safety in healthy adults using continuous Selank. Direct head-to-head comparison with first-line modern anxiety treatments (SSRIs, CBT). Approval by the FDA, EMA, or any non-Russian regulatory body.

The honest read

What's solid:

Selank is a registered prescription drug in Russia with two decades of clinical use behind it. The mechanism is biologically plausible and has been studied at the cellular and animal levels. The reported safety profile, no sedation, no dependence, no significant cognitive impairment, is consistent across the published literature.

What's still unproven:

Whether the Russian clinical findings replicate under Western RCT standards. The clinical literature is largely concentrated in Russian-language journals and from one small group of institutions. Long-term safety in healthy adults using continuous nasal-spray Selank for anxiety hasn't been characterized to modern standards. Comparative effectiveness against SSRIs or CBT hasn't been established.

What's hyped beyond the evidence:

Treating Selank as equivalent to benzodiazepines or SSRIs in clinical effect. The Russian comparator data is interesting but not comprehensive. Claims that it "fixes" anxiety, replaces therapy, or works for severe panic disorder. Anxiety is a heterogeneous condition; broad claims for any single intervention deserve skepticism.

Things to know if you're looking into it

  • How it's used in research: a nasal spray, typically multiple times per day. The intranasal route bypasses the GI tract, which is important because peptides are usually broken down by stomach acid.
  • Regulatory status: approved as a prescription drug in Russia (2009). Not FDA-approved. Not on the FDA Category 2 list. No major Western pharmaceutical company has pursued FDA development.
  • Pairs with Semax: Selank and Semax come from the same Russian peptide-research tradition and are sometimes used together. Semax for cognition, Selank for anxiety. The combination is not formally studied but is common in nootropic communities. Full Semax + Selank blend explainer →
  • Reported tolerability: in the Russian clinical literature and community reports, side effects are uncommon and mostly mild, occasional metallic taste in the mouth, mild nasal irritation, and rarely fatigue at higher doses.
  • Not a replacement for evaluation: persistent or severe anxiety should be evaluated by a clinician. Selank is not a substitute for proper diagnosis and treatment of anxiety disorders, panic disorder, or PTSD.
  • Healthcare provider involvement: recommended for anyone considering use, especially in combination with other psychiatric medications.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Approved in Russia, not FDA-approved. Primarily an intranasal peptide. The standard Russian formulation is "Selank 0.15%" (= 1.5 mg/mL), used as a nasal spray. Almost all published clinical use is intranasal, not subcutaneous. The calculator below shows volume per dose — intranasal users translate that to drops or sprays based on their delivery device (most nasal-spray bottles dispense 0.05–0.1 mL per spray). This is an educational reference, not dosing guidance.
Suggested start
250 mcg/dose
Lower end of nootropic range
Common range
250–500 mcg/dose
1–3× daily
Max dose
1000 mcg/dose
Russian protocols sometimes higher; nootropic ceiling here
Cycle
2–4 wks on
Then 1–2 weeks off
mL
Defaults to 5 mg/mL (about 3.3× stronger than the Russian 0.15% standard) — gives clean math: 250 mcg = 0.05 mL, 500 mcg = 0.10 mL. To match the Russian 0.15% formulation exactly, use ~6.7 mL water.
mcg
Intranasal (standard) or subcutaneous. Typical nasal-spray bottles dispense 0.05–0.1 mL per spray, so a 250 mcg dose at 5 mg/mL is 1 spray (at 0.05 mL) or about half a spray (at 0.1 mL). For SubQ use, the syringe units below apply directly.
Concentration
5.0 mg/mL
Per dose (volume)
0.05 mL
5 units on insulin syringe (SubQ)
Doses per vial
~40
~40 days (~5.7 weeks) of daily dosing

When to stay put vs. adjust

Stay put at 250 mcg once daily (morning) for the first 1–2 weeks. The Selank effect is subtle — reduced background anxiety, easier task transitions, less mental "noise" — not the obvious, sometimes sedating sensation you'd get from a benzodiazepine. The lack of obvious sensation is a feature, not a bug; it's also what makes the trial window matter.

Consider stepping to 500 mcg, or adding a second daily dose, only after at least one week at 250 mcg with clear tolerability. Two smaller doses spread across the day often outperform one larger dose for sustained anxiolytic coverage, since Selank has a relatively short half-life.

Evening dosing is fine for Selank — unlike Semax, the anxiolytic effect doesn't disrupt sleep, and some users specifically dose Selank in the evening to take the edge off anxiety that interferes with sleep onset. This is a practical difference between the two cousin peptides worth knowing.

Watch for occasional metallic taste, mild nasal irritation, or rare fatigue at higher doses. Selank is generally well-tolerated in published Russian clinical use, but the nasal route can cause local irritation if dosed too frequently or the solution is too concentrated. Drop the dose by half or skip a day if any of these appear.

Don't go above 1000 mcg per administration. Russian clinical protocols for severe anxiety can use higher doses, but those are delivered in clinical settings under medical supervision. For nootropic-style daily use, doses above 1000 mcg exit common protocols without clear added benefit.

Cycle off at the 2–4 week mark for 1–2 weeks. Russian protocols are typically course-based rather than continuous. The off-cycle helps prevent receptor adaptation that can blunt the effect over time, and it's also a good moment to re-evaluate whether the underlying anxiety needs other forms of support.

The honest read. The Russian clinical record for generalized anxiety and adjustment disorders is real and includes head-to-head data against medazepam (a benzodiazepine) showing comparable anxiolytic effect without sedation, memory impairment, or dependence concerns. The mechanism (GABA-A modulation, serotonergic effects, BDNF) is biologically plausible. The healthy-adult low-grade-anxiety use case — what most non-Russian users are actually doing — is the weakest-evidenced application. Selank also isn't a substitute for proper evaluation of moderate or severe anxiety; it's an adjunct, not a replacement for clinical care.

For educational and research purposes only. This is not medical advice. Selank is approved as a prescription drug in Russia but is not FDA-approved. Most published clinical evidence is from Russian institutes; Western replication is limited. Persistent or severe anxiety warrants evaluation by a licensed clinician. Consult a healthcare provider before any health decision, especially in combination with other psychiatric medications.

What people often ask

Does it actually work for anxiety?

The Russian clinical literature reports it does, comparable to medazepam without sedation. Whether that holds up in Western-style RCTs hasn't been tested. Anecdotally, many users report meaningful effects; some report little or none.

How is it different from a benzodiazepine?

Benzodiazepines act directly on GABA-A receptors as positive allosteric modulators, that's what produces both the calming effect and the sedation, memory issues, and dependence risk. Selank appears to work indirectly on GABA-A expression and on serotonergic systems, which may be why the cognitive and dependence profiles differ.

How is it different from an SSRI?

SSRIs take 4 to 6 weeks to produce effects and have a different mechanism (serotonin reuptake inhibition). Selank's reported anxiolytic effect is faster, within an hour or so, but the long-term effectiveness picture is less established than for SSRIs.

Is it FDA-approved?

No. Approved in Russia as a prescription drug for anxiety and adjustment disorders. Not approved by the FDA or other major Western regulatory bodies.

Is it addictive?

Russian clinical literature reports no dependence or withdrawal effects, in contrast to benzodiazepines. Long-term Western data doesn't exist to confirm or contradict that.

Can I use it daily?

The Russian clinical use pattern is daily for short courses (typically 14 days). Some research-community users continue beyond that. Long-term safety with continuous use has not been formally characterized.

Are there interactions with other medications?

Formal interaction studies with common psychiatric medications (SSRIs, benzodiazepines, MAOIs, lithium) are limited. Anyone on existing psychiatric medications should involve a clinician before adding Selank.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Approved as a prescription drug in Russia (2009) for generalized anxiety disorder and adjustment disorders. Not approved by the EMA, MHRA, or other major Western regulatory bodies. Not currently on the FDA Category 2 list. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, GABA and serotonergic detail, side effects, and references. Click to expand.

Background and development

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences and the Research Institute of Pharmacology, derived from tuftsin (a naturally occurring four-amino-acid immunomodulating peptide) with an extended C-terminal region for enhanced stability. Developed during the 1990s and registered as a prescription medication in Russia in 2009.

Mechanism of action

GABA-A modulation

Animal studies suggest Selank modulates GABA-A receptor expression and activity in anxiety-related brain regions, contributing to anxiolytic effects without acting as a direct positive allosteric modulator (which is the mechanism that produces benzodiazepine sedation).

Serotonergic effects

Studies report effects on serotonin metabolism and turnover in animal models, providing a second mechanism for anxiolytic effect that more closely parallels SSRI-style action.

BDNF and neuroplasticity

Some research reports increases in BDNF expression in hippocampus and cortex, suggesting neuroplasticity-supporting effects beyond acute anxiolysis.

Immunomodulation

Derived from tuftsin, Selank retains immune-modulating activity. Effects on cytokine profiles relevant to stress-immune interactions have been reported.

Half-life

Plasma half-life is relatively short (minutes), but effects in CNS persist longer than plasma levels would suggest, which is consistent with rapid CNS uptake via the intranasal route and effects mediated through receptor and gene-expression changes.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Intranasal (Russian clinical use): 0.15% solution (1.5 mg/mL), typically 2–3 drops per nostril 2–3 times daily. Total daily dose ranges 600 to 900 mcg.

Treatment duration: Russian clinical protocols use 10 to 14 day courses; some research-community use continues longer. Continuous long-term use has not been formally characterized for safety.

Side effects and safety profile

Reported side effects in published Russian clinical literature and community use:

  • Mild metallic taste shortly after intranasal administration (common, transient)
  • Nasal irritation (uncommon)
  • Mild fatigue at higher doses (uncommon)
  • Headache (rare)

The Russian clinical literature reports no significant interactions with cognition, memory, or psychomotor performance, in contrast to benzodiazepines. Long-term safety with continuous use in healthy adults has not been formally characterized.

References

  1. Semenova TP, Kozlovskaya MM, Zuikov AV, et al. (2007). "Antidepressant and anxiolytic effects of selank in animal experiments." Eksp Klin Farmakol, 70(5), 14–17. PubMed
  2. Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia." Zh Nevrol Psikhiatr Im S S Korsakova, 108(4), 38–48. PubMed
  3. Medvedev VE, Tereshchenko OV, Israelyan AI, et al. (2014). "Optimization of treatment of anxiety-asthenic disorders in patients with cardiovascular disease using selank." Zh Nevrol Psikhiatr Im S S Korsakova, 114(7), 17–22. PubMed
  4. Volkova A, Shadrina M, Kolomin T, et al. (2016). "Selank administration affects the expression of some genes involved in GABAergic neurotransmission." Front Pharmacol, 7, 31. PubMed
  5. Mezhlumyan AG, Tallerova AV, Kolik LG, et al. (2022). "Antidepressant-like effects of selank in mice." Bull Exp Biol Med, 173(2), 199–202. PubMed
For educational and research purposes only. This is not medical advice. Selank is approved in Russia but is not FDA-approved. Consult a licensed healthcare provider before considering any peptide. Persistent or severe anxiety should be evaluated and addressed with first-line treatments. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.